

Unaltered Differentiation Potential of Leukemia and Lymphoma Cell Lines HL-60, THP-1 and U-937 after Nucleofection™

Technical Reference Guide

Introduction

Leukemia and lymphoma cell lines are widely used in immunology and hematology labs to study immunological pathways, such as differentiation or phagocytosis. Suspension cell lines, HL-60 (acute promyelocytic leukemia), THP-1 (acute monocytic leukemia) and U-937 (histiocytic lymphoma), represent frequently used model systems in blood cancer research for these purposes. Though easy to culture, these cells are considered difficult to transfect. With the aid of the Nucleofector™ Technology, suspension cell lines like HL-60, THP-1 and U932 can be transfected with high efficiencies and viabilities, making the investigation of these cells less cumbersome.

Nucleofection™ of HL-60, THP-1 and U-937 Cells

Lonza offers Optimized Protocols, including culture tips and transfection parameters, for HL-60, THP-1 and U-937 cells for the different Nucleofection™ Platforms (please refer to www.lonza.com/nucleofection for more information). Transfection efficiencies between 50 and 65% can be achieved using Nucleofection™ (Figure 1).

As HL-60, THP-1 and U-937 cells are more sensitive to the amount of DNA used in transfection than most other cell lines, one important suggestion when transfecting these cells is to titrate the amount of the DNA substrate. When it comes to the Optimized Protocol for the above mentioned cells, only 0.5 µg DNA (THP-1) and 1 µg DNA (HL-60, U-937) should be used for a 100 µl Nucleocuvette™ Vessel to obtain high viability. In contrast, the majority of Optimized Protocols use 2 µg of pmaxGFP™ Vector.

Higher DNA amounts used in a transfection result in drastic increases in cell death in these cells (Figure 2). This effect on viability needs to be taken into consideration when working with Lonza's pmaxGFP™ Vector or any other plasmid of interest. A simple titration curve of your plasmid is all that is needed to find the optimal amount.




Figure 1: Efficient transfection of HL-60, THP-1 and U-937 cells. HL-60, THP-1 and U-937 cells were transfected by Nucleofection™ with the pmaxGFP™ Vector according to the respective Optimized Protocol. 5 hours post Nucleofection™, cells were analyzed by light and fluorescence microscopy.




Figure 2: Increasing DNA amounts lead to lower cell viability in THP-1 cells transfected by Nucleofection™. THP-1 cells were transfected by Nucleofection™ using increasing amounts of the pmaxGFP™ Vector. 24 hours post Nucleofection™, viability of cells was analyzed (% of living cells compared to untransfected control cells).

How Can HL-60, THP-1 and U-937 Cells Be Differentiated?

Once HL-60, THP-1 or U-937 cells are transfected by Nucleofection™, they can be induced to differentiate easily using any common differentiation protocol. We recommend adding 10 – 100 nM PMA (Phorbol Myristate Acetate) immediately following Nucleofection™ to induce differentiation. Cells are usually fully differentiated within 1 – 4 days after induction. Successful differentiation of HL-60, THP-1 and U-937 cells after Nucleofection™ has been proven in several publications.^{References 1-3.}

What Indicates Differentiation?

Undifferentiated HL-60, THP-1 and U-937 cells are grown in suspension and are round in shape. Once the cells differentiate, they become adherent to the surface and take on an amoeboid or ovoid shape (Figure 3). Using PMA, HL-60, THP-1 and U-937 cells can all be differentiated into macrophage-like cells. HL-60, THP-1 and U-937 cells transfected by Nucleofection™ and differentiated show higher GFP expression levels than non-differentiated cells at 72 – 96 hours post-transfection. The cell count of differentiated cells is lower than for non-differentiated cells, as there is no proliferation during the process of differentiation. However, the percentage of living cells at 72 – 96 hours following transfection is similar between the two populations.

What Factors May Affect Differentiation?

Passage number can have a crucial effect on differentiation of suspension cell lines. THP-1 cells that are at very high passage number can require higher concentrations of PMA and longer incubation to achieve differentiation. These “old” cells can differentiate but will not actually become adherent, whereas younger properly cultured THP-1 cells that have been differentiated look more amoeboid in shape and adhere to their substrate (Figure 4).^{Reference 4.}

Conclusions

Leukemia and lymphoma cell lines HL-60, THP-1 and U-937 can be transfected with high efficiencies using Nucleofection™, while differentiation potential is not affected. This makes these difficult-to-transfect cell lines even more tangible for use in immunology and hematology research.

References

1. Urahama N et al., 2005 Genes Cells 10(12), 1127-1137
2. Liang F et al., 2006 J Biol Chem 281(37), 27526-27538
3. Zada A et al., 2006 Leukemia 20(12), 2137-2146
4. Tsuchiya S et al., 1982 Cancer Res 42, 1530-1536




Figure 3: HL-60, THP-1 and U-937 cells can be differentiated after Nucleofection™. Cells were transfected by Nucleofection™ using the following conditions: HL-60 (1 µg pmaxGFP™ Vector), THP-1 (0.5 µg pmaxGFP™ Vector) and U937 (1 µg pmaxGFP™ Vector) following the respective Optimized Protocol. Immediately after transfection 10 nM (HL-60, U-937) or 20 nM (THP-1) PMA was added to the culture medium. Cells were analyzed by light (A) and fluorescent microscopy (B) 72 hours (THP-1) to 96 hours (HL-60, U-937) post Nucleofection™. maxGFP™ Reporter Protein expression levels were higher in differentiated than in non-differentiated cells.




Figure 4: Passage number can affect differentiation of THP-1 cells. Differentiation of monocytic cell line THP-1 can be induced by treatment with TPA (12-o-tetradecanoylphorbol 13-acetate). Original THP-1 cells show characteristic microvilli and flaps (1A). After treatment with 160 nM TPA, THP-1 cells which have been continuously cultured without cryopreservation for 26 months show decreased number of microvilli and flaps, but still have a round shape (2A). In contrast, original THP-1 cells treated with 160 nM TPA became adherent by showing a macrophage-like flat shape (3A). [Data by permission of The American Association for Cancer Research, Inc.]

Contact Information

North America

Customer Service: 800 638 8174 (toll free)
order.us@lonza.com
Scientific Support: 800 521 0390 (toll free)
scientific.support@lonza.com

Europe

Customer Service: +32 87 321 611
order.europe@lonza.com
Scientific Support: +32 87 321 611
scientific.support.eu@lonza.com

International

Contact your local Lonza distributor
Customer Service: +1 301 898 7025
Fax: +1 301 845 8291
scientific.support@lonza.com

International Offices

Australia	+ 61 3 9550 0883
Belgium	+ 32 87 321 611
Brazil	+ 55 11 2069 8800
France	0800 91 19 81 (toll free)
Germany	0800 182 52 87 (toll free)
India	+91 40 4123 4000
Japan	+ 81 3 6264 0660
Luxemburg	+32 87 321 611
Singapore	+ 65 6521 4379
The Netherlands	0800 022 4525 (toll free)
United Kingdom	0808 234 97 88 (toll free)

Lonza Cologne GmbH – 50829 Cologne Germany

For research use only. Not for use in diagnostic procedures.
The Nucleofector™ Technology is covered by patent and/or patent pending rights owned by the Lonza Group Ltd or its affiliates.

Unless otherwise noted, all trademarks herein are marks of the Lonza Group Ltd or its affiliates. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights.

